Osaic Holdings
ALNY icon

Osaic Holdings’s Alnylam Pharmaceuticals ALNY Stock Holding History

Osaic Holdings’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.6M Sell
45,298
-1,355
-3% -$409K 0.02% 847
2026
Q1 		$15.4M Buy
46,653
+1,935
+4% +$658K 0.02% 678
2025
Q4 		$17.8M Buy
44,718
+19,780
+79% +$8.75M 0.03% 642
2025
Q3 		$11.3M Buy
24,938
+21,151
+559% +$8.61M 0.02% 927
2025
Q2 		$1.2M Buy
3,787
+2,158
+132% +$597K ﹤0.01% 2360
2025
Q1 		$440K Sell
1,629
-3,200
-66% -$822K ﹤0.01% 2994
2024
Q4 		$417K Buy
4,829
+3,465
+254% +$911K ﹤0.01% 2958
2024
Q3 		$375K Buy
1,364
+174
+15% +$45.3K ﹤0.01% 3136
2024
Q2 		$289K Sell
1,190
-373
-24% -$58.9K ﹤0.01% 3254
2024
Q1 		$234K Sell
1,563
-2,032
-57% -$339K ﹤0.01% 3559
2023
Q4 		$688K Sell
3,595
-625
-15% -$106K ﹤0.01% 2880
2023
Q3 		$747K Buy
4,220
+182
+5% +$34.7K ﹤0.01% 2893
2023
Q2 		$772K Buy
4,038
+284
+8% +$56.3K ﹤0.01% 2749
2023
Q1 		$754K Sell
3,754
-2,301
-38% -$484K ﹤0.01% 2749
2022
Q4 		$1.44M Buy
6,055
+2,851
+89% +$608K ﹤0.01% 2020
2022
Q3 		$641K Sell
3,204
-1,654
-34% -$315K ﹤0.01% 2640
2022
Q2 		$709K Sell
4,858
-825
-15% -$117K ﹤0.01% 2601
2022
Q1 		$850K Sell
5,683
-165
-3% -$25.1K ﹤0.01% 2727
2021
Q4 		$994K Buy
5,848
+418
+8% +$77.7K ﹤0.01% 2410
2021
Q3 		$1.02M Buy
5,430
+262
+5% +$49.1K ﹤0.01% 2324
2021
Q2 		$876K Buy
5,168
+604
+13% +$88.5K ﹤0.01% 2485
2021
Q1 		$643K Buy
4,564
+2,313
+103% +$348K ﹤0.01% 2619
2020
Q4 		$292K Buy
2,251
+234
+12% +$31.2K ﹤0.01% 3140
2020
Q3 		$292K Buy
2,017
+333
+20% +$47.3K ﹤0.01% 2902
2020
Q2 		$247K Buy
1,684
+235
+16% +$31.7K ﹤0.01% 2936
2020
Q1 		$159K Buy
+1,449
New +$167K ﹤0.01% 3082

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings's ALNY Position: Q2 2026 in Review

Osaic Holdings reduced its Alnylam Pharmaceuticals (ALNY) stake by 2.9% in Q2 2026, selling an estimated $409K and leaving 45,298 shares worth $13.6M. The position accounts for 0.02% of the portfolio, ranked #847.

Osaic Holdings first reported a position in ALNY in Q1 2020 and has held it in 26 quarters since. The position peaked at $17.8M in Q4 2025. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Osaic Holdings held 45,298 shares of Alnylam Pharmaceuticals worth $13.6M as of Q2 2026.
  • Osaic Holdings sold 1,355 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $409K.
  • Alnylam Pharmaceuticals made up 0.02% of Osaic Holdings's portfolio in Q2 2026, its #847 holding.
  • Osaic Holdings first reported a position in Alnylam Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
  • Osaic Holdings's Alnylam Pharmaceuticals position peaked at $17.8M in Q4 2025.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.